Context Therapeutics To Present Cancer Immunotherapy Data At SITC 2025

Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced two posters will be presented at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, being held November 7–9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, MD.

Context's poster presentations will include a Trial in Progress poster for the Phase 1 clinical trial evaluating CT-95, a Mesothelin x CD3 TCE, as well as a poster for preclinical efficacy, safety and pharmacokinetic data regarding Context's asset, CT-202, a Nectin-4 x CD3 TCE.